Research programme: rare disease mRNA therapeutics - Elpidera

Drug Profile

Research programme: rare disease mRNA therapeutics - Elpidera

Alternative Names: Antibody messenger RNA therapeutics™; mRNA-3704; MT-004; MT-026; MT-033; MT-039; MT-059; MT-088; MT-104

Latest Information Update: 22 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Moderna Therapeutics
  • Class RNA
  • Mechanism of Action Methylmalonyl CoA mutase stimulants; Protein synthesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Methylmalonic acidaemia
  • No development reported Haemophilia

Most Recent Events

  • 14 Sep 2017 Preclinical trials in Methylmalonic acidaemia in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Haemophilia in USA (Parenteral)
  • 12 May 2015 Moderna Therapeutics launches Elpidera to develop mRNA therapeutics for rare diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top